NCT02259556View on ClinicalTrials.gov

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2029

Conditions
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

CART30

Cells will be infused 1 day after the completion of conditioning regimen.

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER